MX2012000680A - Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno. - Google Patents

Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno.

Info

Publication number
MX2012000680A
MX2012000680A MX2012000680A MX2012000680A MX2012000680A MX 2012000680 A MX2012000680 A MX 2012000680A MX 2012000680 A MX2012000680 A MX 2012000680A MX 2012000680 A MX2012000680 A MX 2012000680A MX 2012000680 A MX2012000680 A MX 2012000680A
Authority
MX
Mexico
Prior art keywords
citrate salt
nonaene
hexacosa
trioxa
tetracyclo
Prior art date
Application number
MX2012000680A
Other languages
English (en)
Inventor
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Brian Dymock
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of MX2012000680A publication Critical patent/MX2012000680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a ciertas sales de un 9E-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-19,21,24- triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14, 16,18(26),20,22-nonaeno (compuesto I) que se ha encontrado que tienen propiedades mejoradas. En particular, la presente invención se refiere a la sal de citrato de este compuesto. La invención también se refiere a composiciones farmacéuticas que contienen la sal de citrato y a métodos de uso de la sal de citrato en el tratamiento de ciertas condiciones médicas.
MX2012000680A 2009-07-15 2010-07-14 Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno. MX2012000680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (1)

Publication Number Publication Date
MX2012000680A true MX2012000680A (es) 2012-02-28

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000680A MX2012000680A (es) 2009-07-15 2010-07-14 Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno.

Country Status (18)

Country Link
US (1) US9062074B2 (es)
EP (1) EP2454266B1 (es)
JP (2) JP6013911B2 (es)
CN (1) CN102762577B (es)
AR (2) AR077483A1 (es)
BR (1) BR112012000750B1 (es)
CA (1) CA2768210C (es)
DK (1) DK2454266T3 (es)
ES (1) ES2429525T3 (es)
HR (1) HRP20130941T1 (es)
MX (1) MX2012000680A (es)
PL (1) PL2454266T3 (es)
PT (1) PT2454266E (es)
RU (1) RU2543721C2 (es)
SI (1) SI2454266T1 (es)
SM (1) SMT201300112B (es)
TW (1) TWI537276B (es)
WO (1) WO2011008172A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
EP1951729B1 (en) * 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
US9062074B2 (en) 2015-06-23
HK1178159A1 (en) 2013-09-06
EP2454266B1 (en) 2013-07-10
PL2454266T3 (pl) 2014-01-31
CA2768210A1 (en) 2011-01-20
TWI537276B (zh) 2016-06-11
CN102762577A (zh) 2012-10-31
DK2454266T3 (da) 2013-09-08
TW201107336A (en) 2011-03-01
CN102762577B (zh) 2015-01-07
JP2012533539A (ja) 2012-12-27
JP6013911B2 (ja) 2016-10-25
BR112012000750A8 (pt) 2018-02-06
BR112012000750B1 (pt) 2021-05-25
JP2015164941A (ja) 2015-09-17
AR114987A2 (es) 2020-11-11
EP2454266A1 (en) 2012-05-23
RU2543721C2 (ru) 2015-03-10
HRP20130941T1 (hr) 2013-11-08
US20120196876A1 (en) 2012-08-02
PT2454266E (pt) 2013-10-10
RU2012105044A (ru) 2013-08-20
ES2429525T3 (es) 2013-11-15
WO2011008172A1 (en) 2011-01-20
AR077483A1 (es) 2011-08-31
BR112012000750A2 (pt) 2016-08-09
CA2768210C (en) 2017-08-15
SI2454266T1 (sl) 2013-10-30
SMT201300112B (it) 2013-11-08

Similar Documents

Publication Publication Date Title
PH12013500872A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
IN2012DN01233A (es)
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
NZ708928A (en) Mannose derivatives for treating bacterial infections
PH12012502142A1 (en) Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities
SG178952A1 (en) Chemical compounds
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
PH12013500238B1 (en) N-acylsulfonamide apoptosis promoters
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2011012122A (es) Derivados de tiofeno.
EP2431366A4 (en) NEW CONJUGATED CHLORINE E6 FOLIC ACID COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOUNDS THEREOF FOR THE TREATMENT OF CANCER
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
GB201304501D0 (en) Liquid pharmaceutical compositions
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
PT2454266E (pt) Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
WO2010093615A3 (en) Compounds, their syntheses, compositions, and methods to treat cancer

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CTI BIOPHARMA CORP.

FG Grant or registration
HC Change of company name or juridical status

Owner name: CTI BIOPHARMA CORP.